Abstract
Acalabrutinib is a highly selective, irreversible and orally administered 2nd generation protein kinase inhibitor. The substance is a selective inhibitor of Brutonʼs tyrosine kinase and is currently approved as a monotherapy or in a combination with obinutuzumab for the treatment of adults with previously untreated chronic lymphocytic leukaemia (CLL) and for the treatment of adults with CLL who have received at least one prior therapy.
At the same time, a large number of clinical studies are ongoing to clarify the possible role of acalabrutinib in other indications or to amend additional information in already approved indications.